Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages

医学 促红细胞生成素 肾脏疾病 贫血 透析 海西定 内科学 缺氧诱导因子 红细胞生成 免疫学 生物 生物化学 基因
作者
Akira Mima
出处
期刊:European Journal of Pharmacology [Elsevier BV]
卷期号:912: 174583-174583 被引量:58
标识
DOI:10.1016/j.ejphar.2021.174583
摘要

Anemia is a common feature and complication of chronic kidney disease (CKD). Erythropoiesis-stimulating agents (ESAs) and recombinant human erythropoietin have been used widely in renal anemia treatment. Recently, hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) that may improve the treatment of renal anemia patients were launched. Previous studies indicated that HIF-PHIs may decrease hepcidin levels and modulate iron metabolism, thereby increasing total iron-binding capacity and reducing the need for iron supplementation. Furthermore, HIF-PHIs can reduce inflammation and oxidative stress in CKD. Recombinant erythropoietin has become a routine treatment for patients with CKD and end-stage renal disease with relatively few adverse effects. However, higher doses of recombinant erythropoietin have been demonstrated to be an independent predictor of mortality in patients under hemodialysis. Phase III clinical trials of HIF-PHIs in patients with anemia and dialysis-dependent CKD have shown their efficacy and safety in both non-dialysis and dialysis CKD patients. However, HIFα binds to specific hypoxia-response elements in the vascular endothelial growth factor or retinoic acid-related orphan receptor gamma t (RORγt) promoter, which may be involved in the progression of cancer, psoriasis, and rheumatoid arthritis. In this paper, we have summarized the mechanism, clinical application, and clinical trials of HIF-PHIs in the treatment of renal anemia and aimed to provide an overview of the new drugs in clinical practice, as well as reconsider the advantages and disadvantages of HIF-PHIs and ESAs. Presently, there are not enough clinical studies examining the effects of long-term administration of HIF-PHIs. Therefore, further studies will be needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无极微光的应助被清脆世界采纳,获得20
刚刚
1秒前
大模型的应助被yyySY采纳,获得20
1秒前
1秒前
阳光涫完成签到,获得积分20
2秒前
lei完成签到,获得积分10
3秒前
zhaoxi完成签到 ,获得积分10
4秒前
4秒前
丘比特的应助被zyf采纳,获得10
5秒前
jojo完成签到,获得积分10
5秒前
5秒前
kata完成签到,获得积分10
5秒前
南风完成签到,获得积分10
6秒前
夜寻发布了新的文献求助30
7秒前
无花果的应助被meng采纳,获得10
7秒前
zhikaiyici发布了新的文献求助30
8秒前
刘昊然的老婆完成签到 ,获得积分10
9秒前
liu发布了新的文献求助10
9秒前
Zhao完成签到 ,获得积分10
9秒前
Felix发布了新的文献求助10
10秒前
小蘑菇的应助被xiaoxiao采纳,获得10
11秒前
bad boy发布了新的文献求助10
11秒前
天天快乐的应助被李李李采纳,获得10
11秒前
12秒前
12秒前
小小鱼完成签到,获得积分10
12秒前
英俊的铭的应助被猪大肠采纳,获得10
13秒前
14秒前
14秒前
酷波er的应助被玩家666采纳,获得10
14秒前
14秒前
SciGPT的应助被夜寻采纳,获得30
15秒前
星辰大海的应助被魏同心采纳,获得10
15秒前
打打的应助被arcidia采纳,获得10
16秒前
17秒前
18秒前
MMLi发布了新的文献求助10
18秒前
zyf发布了新的文献求助10
18秒前
FashionBoy的应助被Jasmine采纳,获得10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193